Tuesday, 6 October 2020

Glenmark Pharma gets USFDA nod to market drug for relapsing multiple sclerosis

Drug major Glenmark Pharma said it has received final approval from
the US health regulator for Dimethyl Fumarate delayed-release
capsules, used for the treatment of relapsing forms of multiple
sclerosis in adults.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-pharma-gets-usfda-nod-to-market-drug-for-relapsing-multiple-sclerosis/articleshow/78527839.cms

No comments:

Post a Comment